Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
Demo Company

Earlier Diagnosis of Melanoma May Soon Become Possible Using T-Rays

By BiotechDaily International staff writers
Posted on 23 Sep 2013
Image: Layers of skin can be probed with terahertz rays in search of signs of skin cancer at its earliest stages of development (Photo courtesy of the [US] National Cancer Institute).
Image: Layers of skin can be probed with terahertz rays in search of signs of skin cancer at its earliest stages of development (Photo courtesy of the [US] National Cancer Institute).
New imaging technology has great potential to diagnose cancer at its earliest and most treatable stages.

Anis Rahman, PhD, president and chief technology officer of Applied Research & Photonics (Harrisburg, PA, USA), reported that malignant melanoma, the most lethal type of skin cancer, begins in pigment-producing cells located in the deepest part of the epidermis (the outer layer of the skin). Biochemical alterations are key characteristics of cancer occur in the melanocytes a long time before mole-like melanomas appear on the skin.

“Terahertz radiation is ideal for looking beneath the skin and detecting early signs of melanoma,” Dr. Rahman said. “T-rays are different from X-rays, which are ‘ionizing’ radiation that can cause damage. T-rays are a form of nonionizing radiation, like ordinary visible light, but they can be focused harmlessly below into the body and capture biochemical signatures of events like the start of cancer.”

T-rays occupy a position in the spectrum of electromagnetic radiation, which includes visible light and X-rays, between microwaves and infrared rays. One of the benefits of T-rays is that they penetrate only a few millimeters through skin, cloth, and other nonmetallic material.

Dr. Rahman’s research on T-rays was made through donated samples of human skin, suggesting that the technology could be valuable in diagnosing melanoma. In addition to developing T-rays for cancer diagnostics, Dr. Rahman’s team has effectively utilized them to measure the real-time absorption rates and penetration in the outer layer of skin of topically applied drugs—measurements that until now had not been possible.

Dr. Rahman presented his findings at a symposium held at the annual American Chemical Society (ACS) 2013 meeting, held September 11, 2013, in Indianapolis (IN, USA).

Related Links:
Applied Research & Photonics


Channels

Drug Discovery

view channel
Image: Cancer cells were treated with a control (left) and the overstimulating compound MCB-613 (right) (Photo courtesy of Dr. Lei Wang, Baylor University College of Medicine).

Drug Candidate Propels Cancer Cells into Fatal Overdrive

A candidate drug that destroys cancer cells by stimulating them to produce more proteins than the cells can actually process was shown to kill a wide variety of cancer cells in culture and to inhibit tumor... Read more

Lab Technologies

view channel
Image: The Synergy Neo2 Multi-Mode Reader recently received Cisbio HTRF certification (Photo courtesy of BioTek Instruments Inc.).

High-Speed Multimode Microplate Reader Receives Homogenous Time-Resolved Fluorescence Certification

A new high-performance, high-speed microplate reader has received HTRF (homogenous time-resolved fluorescence) accreditation that certifies that it complies with standards for detection set by a major... Read more

Business

view channel

Innovative Microbial Diagnostics Developer Acquired by Biomedical Giant

A biotech company noted for its development of innovative products in the field of molecular microbiology diagnostics has been acquired by one of the world's largest biomedical corporations. GeneWEAVE BioSciences, Inc.(Los Gatos, CA, USA) and Roche (Basel, Switzerland) have announced that Roche will be purchasing the... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.